TherapeuticsMD, Inc.
TXMD
$1.20
-$0.01-0.83%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 393.00K | 667.00K | 547.00K | 234.00K | 313.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 393.00K | 667.00K | 547.00K | 234.00K | 313.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 393.00K | 667.00K | 547.00K | 234.00K | 313.00K |
| SG&A Expenses | 1.08M | 879.00K | 1.31M | 1.23M | 1.32M |
| Depreciation & Amortization | 95.00K | 100.00K | 96.00K | 180.00K | 133.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.18M | 979.00K | 1.41M | 1.41M | 1.46M |
| Operating Income | -783.00K | -312.00K | -859.00K | -1.18M | -1.14M |
| Income Before Tax | -668.00K | 83.00K | -567.00K | -1.05M | -809.00K |
| Income Tax Expenses | -32.00K | -31.00K | -- | -- | -- |
| Earnings from Continuing Operations | -636.00K | 114.00K | -567.00K | -1.05M | -809.00K |
| Earnings from Discontinued Operations | -17.00K | 138.00K | -42.00K | -40.00K | 75.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -653.00K | 252.00K | -609.00K | -1.09M | -734.00K |
| EBIT | -783.00K | -312.00K | -859.00K | -1.18M | -1.14M |
| EBITDA | -688.00K | -212.00K | -763.00K | -999.00K | -1.01M |
| EPS Basic | -0.06 | 0.02 | -0.05 | -0.09 | -0.06 |
| Normalized Basic EPS | -0.03 | -0.06 | -0.03 | -0.06 | -0.04 |
| EPS Diluted | -0.06 | 0.02 | -0.05 | -0.09 | -0.06 |
| Normalized Diluted EPS | -0.03 | -0.06 | -0.03 | -0.06 | -0.04 |
| Average Basic Shares Outstanding | 11.55M | 11.53M | 11.53M | 11.53M | 11.53M |
| Average Diluted Shares Outstanding | 11.55M | 11.53M | 11.53M | 11.53M | 11.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |